Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology ...
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company headquartered in Tarpon Springs, Florida, with operations in Denmark and the United States. Founded in 2004 by Steen Knudsen as Medical Prognosis Institute A/S, the company rebranded to Allarity Therapeutics in 2017. It focuses on developing personalized cancer therapies guided ...Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company headquartered in Tarpon Springs, Florida, with operations in Denmark and the United States. Founded in 2004 by Steen Knudsen as Medical Prognosis Institute A/S, the company rebranded to Allarity Therapeutics in 2017. It focuses on developing personalized cancer therapies guided by its proprietary Drug Response Predictor (DRP) technology, which uses genetic biomarkers to select patients likely to respond to specific drugs, aiming to improve efficacy and reduce unnecessary side effects.
The company's pipeline includes several investigational oncology drugs: Stenoparib, a PARP inhibitor in Phase 2 trials for recurrent ovarian cancer and small cell lung cancer; Dovitinib, a pan-tyrosine kinase inhibitor for renal cell carcinoma; IXEMPRA (ixabepilone), a microtubule inhibitor for metastatic breast cancer; LiPlaCis, a liposomal cisplatin formulation in Phase 2 for metastatic breast cancer; and 2X-111, a liposomal doxorubicin in Phase 2 for metastatic breast cancer and glioblastoma. These assets have been in-licensed or acquired, reflecting a strategy of drug repurposing and development.
Financially, Allarity is a small company with 8 full-time employees (as of the latest data). As of the most recent reporting, it has a market cap of approximately $22 million, with a stock price around $1.40. The company has limited revenue, with R&D and SG&A expenses exceeding revenue, leading to negative profitability and operating cash flow. Key financial metrics include a negative net profit margin, negative return on equity, and a high debt-to-equity ratio, indicating financial challenges typical of clinical-stage firms. The company has raised capital through public offerings and exercises warrants to fund operations.
Under CEO Thomas H. Jensen, who also co-founded the company, Allarity continues to advance its clinical trials, aiming to bring personalized cancer therapies to market. The company's unique DRP technology sets it apart, potentially offering a more efficient path to drug approval by targeting responders. However, the inherent risks of clinical development and financial sustainability remain significant. Allarity's long-term vision is to improve cancer treatment outcomes by matching patients with the most effective therapies, thereby reducing trial-and-error medicine and enhancing cost-effectiveness in oncology care.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$320000
—
-100.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-11.2M
+54.2%
-23.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+100.0%
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-3939.1%
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-3509.7%
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-14.8M
+16.0%
+43.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-4633.8%
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
14.2%
+24.6%
+102.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.13x
+3.2%
-9.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
